Tango Therapeutics Inc (TNGX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.32B
Last updated: Nov 17, 2026 at 11:06 AM ET
Tango Therapeutics Inc (TNGX) Stock Forecast
Analysts expect Tango Therapeutics (TNGX) to earn -$1.46 per share in the fiscal year ending Dec 31, 2026. Of 13 analysts, 12 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 7.7% |
| Buy | 11 | 84.6% |
| Hold | 1 | 7.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$1.46
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.80
- EPS consensus, revenue $3.14M
- Next report
- Mar 3, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.46 | -$1.63 to -$1.14 | 13 | N/A | N/A | 12 |
| Dec 31, 2027 | -$1.80 | -$2.36 to -$1.24 | 12 | $3.14M | N/A | 10 |
Quarterly Estimates
The EPS consensus falls from -$0.41 for the quarter ending Dec 31, 2026 to -$0.43 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.41 | -$0.47 to -$0.33 | 15 | N/A | N/A | 14 |
| Mar 31, 2027 | -$0.43 | -$0.50 to -$0.34 | 4 | $1.58M | N/A | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 5 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 3 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.38.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.46 | -$1.40 | -$1.40 | -$1.40 | -$1.38 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.80 | -$1.67 | -$1.69 | -$1.69 | -$1.64 | N/A |
| Quarter ending Mar 31, 2027 | -$0.43 | -$0.38 | -$0.37 | -$0.37 | -$0.36 | N/A |
Frequently Asked Questions About TNGX
What is the TNGX stock forecast?
Consensus analyst estimates put Tango Therapeutics's EPS at -$1.46 for the fiscal year ending Dec 31, 2026. The consensus rating from 13 analysts is Buy.
How do analysts rate TNGX stock?
Of 13 analysts covering Tango Therapeutics, 1 rates it Strong Buy, 11 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TNGX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.46, with estimates from -$1.63 to -$1.14 from 13 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.80, with estimates from -$2.36 to -$1.24 from 12 analysts.
What revenue do analysts expect from Tango Therapeutics next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.14M.
How many analysts cover TNGX?
13 analysts rate Tango Therapeutics stock, and 13 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TNGX pages: Overview, Earnings, Forecast, Financials, Competitors